Clovis's Rubraca Leapfrogs Rivals In Ovarian Cancer As ARIEL3 Hits
Clovis Oncology is forging ahead with a filing for a maintenance indication for its PARP inhibitor Rubraca in a broad ovarian cancer population as new data from ARIEL3 blow the field wide open.
You may also be interested in...
EU CHMP To Decide On New Drugs For Asthma, Diabetes, Hemophilia A, Ovarian Cancer – And Roche’s Ocrevus
Products for a wide range of diseases are expecting a CHMP opinion this week, including orphan drugs for ovarian cancer, eosinophilic esophagitis, and CMV infection, and therapies for asthma, diabetes, and hemophilia A. Roche will be hoping its multiple sclerosis drug Ocrevus can finally clear the CHMP hurdle.
Lynparza Poised For Growth With Broad Ovarian Cancer Approval
AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing, posing a threat to Tesaro's reigning Zejula.
The PARP Combo Race Is On: Clovis And Bristol Partner On Rubraca
Amidst excitement over the potential of PD-1/PARP inhibitor combos in multiple tumor types, Clovis signs a non-exclusive agreement to test Rubraca with Bristol's Opdivo in ovarian, breast and prostate cancer.